Compare GFF & ABCL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GFF | ABCL |
|---|---|---|
| Founded | 1959 | 2012 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Building Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.2B | 4.1B |
| IPO Year | 1994 | 2020 |
| Metric | GFF | ABCL |
|---|---|---|
| Price | $101.46 | $11.86 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 7 | 13 |
| Target Price | ★ $126.86 | $17.17 |
| AVG Volume (30 Days) | 307.2K | ★ 3.7M |
| Earning Date | 11-18-2026 | 11-09-2026 |
| Dividend Yield | ★ 0.86% | N/A |
| EPS Growth | N/A | ★ 10.91 |
| EPS | ★ 2.97 | N/A |
| Revenue | ★ $2,519,926,000.00 | $75,128,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $3.13 | $7.12 |
| P/E Ratio | $36.20 | ★ N/A |
| Revenue Growth | N/A | ★ 160.56 |
| 52 Week Low | $65.01 | $2.75 |
| 52 Week High | $108.57 | $14.98 |
| Indicator | GFF | ABCL |
|---|---|---|
| Relative Strength Index (RSI) | 57.52 | 47.54 |
| Support Level | $88.25 | $11.78 |
| Resistance Level | $108.57 | $13.21 |
| Average True Range (ATR) | 3.21 | 0.93 |
| MACD | 0.67 | -0.11 |
| Stochastic Oscillator | 56.76 | 33.87 |
Griffon Corp manufactures and markets residential, commercial and industrial garage doors to professional installing dealers and home center retail chains. It also provides non-powered landscaping products for homeowners and professionals. Its operating segments include Consumer and Professional Products: is a provider of branded consumer and professional tools; residential, industrial and commercial fans; home storage and organization products; and Home and Building Products conducts its operations through Clopay Corporation (Clopay). Clopay is the manufacturer and marketer of garage doors and rolling steel doors in North America. The company generates a majority of its revenue from the Home and Building Products segment. Operates in USA, Europe, Canada, Australia, and Others.
AbCellera Biologics Inc is a clinical-stage biotechnology company focused on discovering and developing first-in-class antibody medicines for indications with high unmet medical need. It has built a platform for advancing antibody drug programs that the company believes provides it with a competitive advantage in addressing challenging, high-value targets such as complex transmembrane proteins and novel modalities, including multispecifics and antibody-drug conjugates. Organisation's pipeline includes two drug candidates in clinical development, two development candidates in Investigational New Drug (IND/Clinical Trial Application (CTA)-enabling activities, and more than 20 active discovery programs across multiple modalities and indications.